Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine's Effects on the BrainBusiness Wire • 05/09/22
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality' Global Summit on Psychedelic-Assisted Therapies and MedicineBusiness Wire • 05/05/22
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022Business Wire • 04/22/22
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive DisorderBusiness Wire • 04/21/22
The Power Play by The Market Herald Releases Interviews with Cybin and Baroyeca Gold & SilverAccesswire • 04/13/22
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMTBusiness Wire • 04/13/22
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic MoleculesBusiness Wire • 04/08/22
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the BrainBusiness Wire • 03/31/22
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical TrialBusiness Wire • 03/29/22
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting ParticipantsBusiness Wire • 03/24/22
Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022Business Wire • 03/16/22
Cybin, Deepak Chopra Announce Partnership For Psychedelics Awareness And EducationBenzinga • 02/16/22
The Chopra Foundation Announces Partnership with Cybin Inc. to Increase Education and Awareness of the Potential Use of Psychedelics in Supporting Well-Being and Mental HealthPRNewsWire • 02/15/22
Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event.Benzinga • 02/14/22
Cybin, Inc. (CYBN) CEO Douglas Drysdale on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 02/10/22
Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety DisordersBenzinga • 02/09/22
Cybin Receives U.S. Patent For Its Proprietary Compound To Treat Anxiety DisordersBenzinga • 02/09/22
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety DisordersBusiness Wire • 02/09/22
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022Business Wire • 01/27/22